For Immediate Release **December 11, 2024**

Acuitas Scientist Presented at LNP Immunogenicity & Toxicity Summit

Vancouver, B.C. – Sean Semple, Vice President of Preclinical Research, of Acuitas Therapeutics, Inc., the global leader in lipid nanoparticle (LNP) technology, presented at the 3rd LNP Immunogenicity & Toxicity Summit in Boston on December 10.

Mr. Semple spoke on optimizing ionizable lipid and LNP properties to improve safety. The presentation included research on LNP toxicity profiles; the impact of lipid, cargo and LNP properties on safety parameters; and correlations with pharmacokinetics and tissue distribution. You can view his presentation here.

About the LNP Immunogenicity & Toxicity Summit

The LNP Immunogenicity & Toxicity Summit provides participants with the opportunity to join forces with industry experts striving to transform non-clinical and clinical safety risk assessments for LNP and testing strategies to confidently measure, predict and monitor LNP safety profiles to progress and support the development of safe and regulatory compliant vaccines, as well as gene and cell therapies.

About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics is the global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' LNP technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATTRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works on identification of potent new lipids to enable partners to develop improved and new vaccines to prevent a range of infectious diseases (i.e., malaria, HIV/AIDS and tuberculosis), multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-